Juno is led by a management team with diverse backgrounds and talents, with the common goal of revolutionizing medicine through developing a broadly applicable cell-based platform.
President & CEO
Steve Harr, M.D.
CFO & Head of Corporate Development
Hyam Levitsky, M.D.
EVP, Chief Scientific Officer
Corsee Sanders is our Executive Vice President, Development Operations and joined Juno in January 2017. She is responsible for the planning, management, execution, analysis, and reporting of Juno’s clinical trials. Prior to joining Juno, Dr. Sanders was Senior Vice President and Head of Global Clinical Operations and Industry Collaborations at Roche Pharmaceuticals, where she also served as Head of Global Biometrics and Development Innovation. Previously, she worked in a number of senior leadership roles at Genentech, Inc., where she was instrumental in the development of some of Genentech’s most successful products, including Herceptin and Avastin. At Genentech, her responsibilities covered a range of functions, including biostatistics, epidemiology, health economics and outcomes research, data management, medical writing, information technology, and biosample management. Dr. Sanders holds bachelor’s and master’s degrees in statistics from the University of the Philippines, and received a master’s degree and doctorate in statistics from the Wharton School at the University of Pennsylvania.
Mark Gilbert, M.D.
SVP, Chief Medical Officer
Barney Cassidy, J.D.
General Counsel & Secretary
SVP, Regulatory and Quality Assurance
Andy Walker, Ph.D.
Andy earned his Ph.D. in Chemical Engineering from the University of California, Berkeley, and a B.S. in Chemical Engineering from the University of Washington. Andy also has a Management of Technology certificate from the UC Berkeley Haas School of Business.
Ken Mohler, Ph.D.